Ab­b­Vie touts Skyrizi ul­cer­a­tive col­i­tis da­ta as it eyes an­oth­er in­di­ca­tion

Ab­b­Vie has tout­ed Skyrizi as a key pil­lar of its fu­ture be­yond Hu­mi­ra, and on Thurs­day, the com­pa­ny read out re­sults sug­gest­ing the IL-23 in­hibitor suc­ceed­ed as a main­te­nance ther­a­py for ul­cer­a­tive col­i­tis.

The phar­ma gi­ant re­port­ed that con­tin­ued treat­ment with Skyrizi (risankizum­ab) led to a “sig­nif­i­cant­ly high­er” rate of clin­i­cal re­mis­sion from ul­cer­a­tive col­i­tis com­pared to pa­tients who re­ceived on­ly in­duc­tion ther­a­py. The topline re­sults come just a few months af­ter Ab­b­Vie an­nounced that its Phase III in­duc­tion study met the pri­ma­ry and all sec­ondary end­points in adults with mod­er­ate­ly to se­vere­ly ac­tive ul­cer­a­tive col­i­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER